These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33123544)

  • 1. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.
    Boregowda U; Perisetti A; Nanjappa A; Gajendran M; Kutti Sridharan G; Goyal H
    Front Med (Lausanne); 2020; 7():586221. PubMed ID: 33123544
    [No Abstract]   [Full Text] [Related]  

  • 2. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
    Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
    Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review.
    Kaye AG; Siegel R
    PeerJ; 2020; 8():e10322. PubMed ID: 33194450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019.
    Gao Q; Yin X; Tan B; Wang J; Chen J; Zhao B; Yang Q; Li Z
    BMC Infect Dis; 2022 Dec; 22(1):929. PubMed ID: 36503381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab in the treatment of COVID-19-a meta-analysis.
    Avni T; Leibovici L; Cohen I; Atamna A; Guz D; Paul M; Gafter-Gvili A; Yahav D
    QJM; 2021 Nov; 114(8):577-586. PubMed ID: 34010403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
    Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
    Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies.
    Malgie J; Schoones JW; Pijls BG
    Clin Infect Dis; 2021 Jun; 72(11):e742-e749. PubMed ID: 32964913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.
    Burlacu R; London J; Fleury A; Sené T; Diallo A; Meyssonnier V; Zeller V; Galland J; Huscenot T; Rubenstein E; Trouiller P; Amathieu R; Kutter J; Blondeel D; Lejour G; Mouly S; Lidove O; Wladimir M; Sène D
    Medicine (Baltimore); 2021 May; 100(21):e26023. PubMed ID: 34032722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis.
    Petrelli F; Cherri S; Ghidini M; Perego G; Ghidini A; Zaniboni A
    World J Methodol; 2021 May; 11(3):95-109. PubMed ID: 34026583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.
    Kotak S; Khatri M; Malik M; Malik M; Hassan W; Amjad A; Malik F; Hassan H; Ahmed J; Zafar M
    Cureus; 2020 Oct; 12(10):e10869. PubMed ID: 33178522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies.
    Viswanatha GL; Anjana Male CKVLSN; Shylaja H
    Clin Exp Rheumatol; 2022 Mar; 40(3):634-646. PubMed ID: 34251307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    Piscoya A; Parra Del Riego A; Cerna-Viacava R; Rocco J; Roman YM; Escobedo AA; Pasupuleti V; White CM; Hernandez AV
    PLoS One; 2022; 17(6):e0269368. PubMed ID: 35657993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis.
    Alkofide H; Almohaizeie A; Almuhaini S; Alotaibi B; Alkharfy KM
    Int J Infect Dis; 2021 Sep; 110():320-329. PubMed ID: 34273515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis.
    Conti V; Corbi G; Sellitto C; Sabbatino F; Maci C; Bertini N; De Bellis E; Iuliano A; Davinelli S; Pagliano P; Filippelli A
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.
    Berardicurti O; Ruscitti P; Ursini F; D'Andrea S; Ciaffi J; Meliconi R; Iagnocco A; Cipriani P; Giacomelli R
    Clin Exp Rheumatol; 2020; 38(6):1247-1254. PubMed ID: 33275094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.